Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin.
- Brom, Maarten
- Woliner-van der Weg, Wietske
- Joosten, Lieke
- Frielink, Cathelijne
- Bouckenooghe, Thomas
- Rijken, Paul
- Andralojc, Karolina
- Göke, Burkhard J
- de Jong, Marion
- Eizirik, Decio L.
- Béhé, Martin
- Lahoutte, Tony
- Oyen, Wim J G
- Tack, Cees J
- Janssen, Marcel
- Boerman, Otto C
- Gotthardt, Martin
Publication date
January 2014
DOI Publisher
Springer Science and Business Media LLCAbstract
A reliable method for in vivo quantification of pancreatic beta cell mass (BCM) could lead to further insight into the pathophysiology of diabetes. The glucagon-like peptide 1 receptor, abundantly expressed on beta cells, may be a suitable target for imaging. We investigated the potential of radiotracer imaging with the GLP-1 analogue exendin labelled with indium-111 for determination of BCM in vivo in a rodent model of beta cell loss and in patients with type 1 diabetes and healthy individuals.Journal ArticleResearch Support, N.I.H. ExtramuralResearch Support, Non-U.S. Gov'tSCOPUS: ar.jinfo:eu-repo/semantics/publishe
Add to ORKG